These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22989690)

  • 1. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H; Tobudic S; Ramharter M; Elandt K; Sperr WR; Redlberger-Fritz M; Popow-Kraupp T; Jäger U; Zielinski CC; Burgmann H
    Vaccine; 2012 Nov; 30(48):6864-70. PubMed ID: 22989690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment.
    Mackay HJ; McGee J; Villa D; Gubbay JB; Tinker LM; Shi L; Kuruvilla J; Wang L; MacAlpine K; Oza AM
    J Clin Virol; 2011 Mar; 50(3):212-6. PubMed ID: 21168361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy-treated patients.
    Cherif H; Höglund M; Pauksens K
    Eur J Haematol; 2013 May; 90(5):413-9. PubMed ID: 23444982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM
    Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P; Changsirikulchai S; Limkunakul C; Prachukthum P; Punpiput P; Buppanharun R; Chotpitayasunondh C
    Vaccine; 2012 Feb; 30(6):1108-14. PubMed ID: 22178515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL; Rouleau D; Fortin C; Toma E; Sylla M; Cyr L; Cote S; Baz M; Sampalis J; Trautman L; Sékaly RP; Boivin G
    Vaccine; 2011 Feb; 29(7):1359-63. PubMed ID: 21185423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a China-made monovalent pandemic (H1N1) 2009 influenza A vaccine in healthcare workers in Guangzhou, China.
    Zhan Y; Yang Z; Li L; Ye D; Wu H; Fu R; Zhao S; Wang Y; Zhou R; Chen R
    Jpn J Infect Dis; 2011; 64(3):190-4. PubMed ID: 21617301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial.
    Uno S; Kimachi K; Kei J; Miyazaki K; Oohama A; Nishimura T; Ibaragi K; Odoh K; Kudo Y; Kino Y
    Microbiol Immunol; 2011 Nov; 55(11):783-9. PubMed ID: 21895745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies.
    Mariotti J; Spina F; Carniti C; Anselmi G; Lucini D; Vendramin A; Pregliasco F; Corradini P
    Eur J Haematol; 2012 Aug; 89(2):111-9. PubMed ID: 22540245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response to 2009 pandemic H1N1 influenza virus A monovalent vaccine in children with cancer.
    Yen TY; Jou ST; Yang YL; Chang HH; Lu MY; Lin DT; Lin KH; Huang LM; Chang LY
    Pediatr Blood Cancer; 2011 Dec; 57(7):1154-8. PubMed ID: 21425448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.
    Vajo Z; Tamas F; Sinka L; Jankovics I
    Lancet; 2010 Jan; 375(9708):49-55. PubMed ID: 20018367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab.
    Berglund A; Willén L; Grödeberg L; Skattum L; Hagberg H; Pauksens K
    Acta Oncol; 2014 Sep; 53(9):1212-20. PubMed ID: 24865118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.